Shorts Action: A Reversal for Vivus Incorporated (NASDAQ:VVUS) Is Near. The Stock Has Decrease in Shorts

November 21, 2016 - By Louis Casey   ·   0 Comments

Shorts Action: A Reversal for Vivus Incorporated (NASDAQ:VVUS) Is Near. The Stock Has Decrease in Shorts

The stock of Vivus Incorporated (NASDAQ:VVUS) registered a decrease of 4.75% in short interest. VVUS’s total short interest was 6.88M shares in November as published by FINRA. Its down 4.75% from 7.22 million shares, reported previously. With 212,400 shares average volume, it will take short sellers 32 days to cover their VVUS’s short positions. The short interest to Vivus Incorporated’s float is 8.11%. The stock closed at $1.23 during the last session. It is down 31.28% since April 19, 2016 and is downtrending. It has underperformed by 35.15% the S&P500.

VIVUS, Inc. is a biopharmaceutical company. The company has a market cap of $135.57 million. The Firm operates in the development and commercialization of therapeutic products segment. It currently has negative earnings. It provides over two therapies approved by the Food and Drug Association , which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil) for erectile dysfunction (ED).

Insitutional Activity: The institutional sentiment increased to 0.58 in Q2 2016. Its up 0.02, from 0.56 in 2016Q1. The ratio is positive, as 23 funds sold all VIVUS, Inc. shares owned while 29 reduced positions. 17 funds bought stakes while 12 increased positions. They now own 38.40 million shares or 16.81% less from 46.16 million shares in 2016Q1.
First Manhattan has 41,400 shares for 0% of their US portfolio. Jpmorgan Chase And has 0% invested in the company for 90,097 shares. Schulhoff &, a Ohio-based fund reported 11,000 shares. Whittier Tru holds 0% of its portfolio in VIVUS, Inc. (NASDAQ:VVUS) for 2,500 shares. Meditor Gp has 0.73% invested in the company for 1.60M shares. The California-based Blackrock Institutional Communication Na has invested 0% in VIVUS, Inc. (NASDAQ:VVUS). Royal Fincl Bank Of Canada has 270,430 shares for 0% of their US portfolio. Maple Management Inc has 0.01% invested in the company for 24,500 shares. Laurion Capital Management Ltd Partnership has 214,400 shares for 0% of their US portfolio. Commerzbank Aktiengesellschaft Fi accumulated 27,490 shares or 0% of the stock. Millennium Ltd Limited Liability Company last reported 634,195 shares in the company. The New York-based Jane Street Group has invested 0% in VIVUS, Inc. (NASDAQ:VVUS). Elkhorn Prns Ltd Partnership accumulated 0.01% or 14,800 shares. The Massachusetts-based Panagora Asset Mngmt has invested 0% in VIVUS, Inc. (NASDAQ:VVUS). North Tide Cap last reported 1.7% of its portfolio in the stock.

Insider Transactions: Since July 1, 2016, the stock had 0 buys, and 3 sales for $14,690 net activity. On Tuesday, August 2 the insider Varghese Santosh T sold $13,438.

VIVUS, Inc. (NASDAQ:VVUS) Ratings Coverage

Out of 2 analysts covering Vivus (NASDAQ:VVUS), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Vivus has been the topic of 3 analyst reports since July 31, 2015 according to StockzIntelligence Inc. The stock of VIVUS, Inc. (NASDAQ:VVUS) has “Outperform” rating given on Friday, July 31 by RBC Capital Markets. On Wednesday, August 5 the stock rating was upgraded by Zacks to “Hold”. The firm earned “Buy” rating on Thursday, November 5 by WallachBeth Capital.

VVUS Company Profile

VIVUS, Inc., incorporated on May 16, 1996, is a biopharmaceutical company. The Firm operates in the development and commercialization of therapeutic products segment. It provides over two therapies approved by the United States Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended release) for chronic weight management and STENDRA (Avanafil) for erectile dysfunction (ED). The Firm is also developing Qsymia for the treatment of Obstructive Sleep Apnea (OSA) and diabetes. STENDRA is also approved by the European Commission (EC), under the name, SPEDRA, for the treatment of ED in the Europe.

More news for VIVUS, Inc. (NASDAQ:VVUS) were recently published by: Equitiesfocus.com, which released: “VIVUS, Inc. (NASDAQ:VVUS) Quarterly EPS From Continuing Operations Stands At …” on November 21, 2016. Fool.com‘s article titled: “Why VIVUS, Inc. Stock Descended 14% in December” and published on January 09, 2015 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Louis Casey


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>